Filspari Tablet, Film Coated
Product Images NDC 68974-200

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Filspari (NDC 68974-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Travere Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Effective Birth Control Options (Birth Control Options)

This text lists different birth control options including intrauterine devices, hormonal contraceptives, barrier methods, and sterilization. It presents a chart with four columns showing the different methods available. There are also different options for spermicide and hormonal treatments. The list concludes with an injection method.*

FDA Label Image

Figure 1 (Figure 1)

This appears to be a statistical report on the percent change of a drug called Irbesartan. The report shows the Adjusted Geometric Mean Percent Change at two different time points (not specified) and the corresponding confidence intervals. The numbers listed below the drug name may be related to the study participants or measurements taken. Further context is needed to fully understand the report.*

FDA Label Image

Sparsentan Structure (Sparsentan Structure)

FDA Label Image

Principal Display Panel (200 mg Tablet Label)

This is a description of a medication called Sparsentan. The tablets are film-coated and contain 200mg of Sparsentan. The recommended dosage and prescribing information should be followed carefully. The tablets should be stored at a temperature between 20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted. The medication guide should be dispensed along with the tablets to the patient, and they should be stored in their original container at room temperature. The medication is manufactured by Catalent in Kansas City, and it is distributed by Travere Therapeutics in San Diego, CA.*

FDA Label Image

Principal Display Panel (400 mg Tablet Label)

Each tablet of FILSPARI contains 400mg of sparsentan, an ingredient with recommended dosage as stated in the prescribing information. The tablets should be stored between 20°C to 25°C (68°F to 77°F) and can be excursed between 15°C and 30°C (59°F and 86°F). The tablets should be stored in their original container and protected from children. The NDC code for FILSPARI (sparsentan) tablets is 68974-400-30. FILSPARI (sparsentan) tablets are for prescription only, and patients should be provided with medication labels. FILSPARI is manufactured by Travere Therapeutics in San Diego, CA and by Catalent in Kansas City, MO 64137.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.